Alexa P. Kollmeier

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Philip J. Mease, Proton Rahman, Alice B. Gottlieb et al. · The Lancet · 2020 · 325 citations · Full text

Rheumatology, Autoimmune Disease, Placebo-controlled Phase 3 +11

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke et al. · The Lancet · 2020 · 307 citations

Rheumatology, Autoimmune Disease, Placebo-controlled Phase 3 +11

<scp>Long‐Term</scp> Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase <scp>III</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Study Conducted in <scp>Biologic‐Naive</scp> Patients With Active Psoriatic Arthritis

Iain B. McInnes, Proton Rahman, Alice B. Gottlieb et al. · Arthritis & Rheumatology · 2021 · 97 citations · Full text

Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies

Philip J. Mease, Philip Helliwell, Dafna D. Gladman et al. · The Lancet Rheumatology · 2021 · 94 citations

Inflammation, Rheumatology, Rheumatoid Disorder +13

The Histamine H4 Receptor Antagonist, JNJ 39758979, Is Effective in Reducing Histamine-Induced Pruritus in a Randomized Clinical Study in Healthy Subjects

Alexa P. Kollmeier, Klaus Francke, Bin Chen et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 86 citations